TY - JOUR
T1 - Impact and Advances in the Role of Bacterial Extracellular Vesicles in Neurodegenerative Disease and Its Therapeutics
AU - Iyaswamy, Ashok
AU - Lu, Kejia
AU - Guan, Xin Jie
AU - Kan, Yuxuan
AU - Su, Chengfu
AU - Liu, Jia
AU - Jaganathan, Ravindran
AU - Vasudevan, Karthick
AU - Paul, Jeyakumari
AU - Thakur, Abhimanyu
AU - Li, Min
N1 - This study was supported by the Knowledge Transfer Office and Research Committee of Hong Kong Baptist University (HKBU-MPCF-003-2022-23), Hong Kong Health and Medical Research Fund (HMRF/17182541, HMRF/17182551, HMRF/09203776), and the General Research Fund from Research Grant Council (HKBU 12302620, 1230202, and 12101022) of Hong Kong Government.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/7
Y1 - 2023/7
N2 - Bacterial Extracellular Vesicles (BEVs) possess the capability of intracellular interactions with other cells, and, hence, can be utilized as an efficient cargo for worldwide delivery of therapeutic substances such as monoclonal antibodies, proteins, plasmids, siRNA, and small molecules for the treatment of neurodegenerative diseases (NDs). BEVs additionally possess a remarkable capacity for delivering these therapeutics across the blood–brain barrier to treat Alzheimer’s disease (AD). This review summarizes the role and advancement of BEVs for NDs, AD, and their treatment. Additionally, it investigates the critical BEV networks in the microbiome–gut–brain axis, their defensive and offensive roles in NDs, and their interaction with NDs. Furthermore, the part of BEVs in the neuroimmune system and their interference with ND, as well as the risk factors made by BEVs in the autophagy–lysosomal pathway and their potential outcomes on ND, are all discussed. To conclude, this review aims to gain a better understanding of the credentials of BEVs in NDs and possibly discover new therapeutic strategies.
AB - Bacterial Extracellular Vesicles (BEVs) possess the capability of intracellular interactions with other cells, and, hence, can be utilized as an efficient cargo for worldwide delivery of therapeutic substances such as monoclonal antibodies, proteins, plasmids, siRNA, and small molecules for the treatment of neurodegenerative diseases (NDs). BEVs additionally possess a remarkable capacity for delivering these therapeutics across the blood–brain barrier to treat Alzheimer’s disease (AD). This review summarizes the role and advancement of BEVs for NDs, AD, and their treatment. Additionally, it investigates the critical BEV networks in the microbiome–gut–brain axis, their defensive and offensive roles in NDs, and their interaction with NDs. Furthermore, the part of BEVs in the neuroimmune system and their interference with ND, as well as the risk factors made by BEVs in the autophagy–lysosomal pathway and their potential outcomes on ND, are all discussed. To conclude, this review aims to gain a better understanding of the credentials of BEVs in NDs and possibly discover new therapeutic strategies.
KW - Alzheimer’s disease
KW - bacterial extracellular vesicles
KW - nanocarriers
KW - neurodegenerative disease
KW - therapeutics
UR - http://www.scopus.com/inward/record.url?scp=85174037235&partnerID=8YFLogxK
U2 - 10.3390/biomedicines11072056
DO - 10.3390/biomedicines11072056
M3 - Journal article
AN - SCOPUS:85174037235
SN - 2227-9059
VL - 11
JO - Biomedicines
JF - Biomedicines
IS - 7
M1 - 2056
ER -
